8158 — China Regenerative Medicine International Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Market Cap
HK$91.28m
Enterprise Value
HK$134.41m
Revenue
HK$72.06m

Annual income statement for China Regenerative Medicine International, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	283	232	69.5	90.6	72.1
Cost of Revenue
Gross Profit	67.7	37.6	19.4	57.7	41.9
Selling / General / Administrative Expenses
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	259	223	176	71.7	55.7
Operating Profit	23.7	9.05	-107	18.9	16.4
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	64.3	8.27	-108	17.8	15.2
Provision for Income Taxes
Net Income After Taxes	51.8	4.55	-108	17.8	27.5
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	13.3	4.55	-108	17.8	27.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	13.3	4.55	-108	17.8	27.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.168	0.014	-0.376	0.115	0.09